Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption-Reference-Cited by-同舟云学术

Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption

Published:2020-03-23 Issue:4 Volume:26 Page:498-501
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Colby Donn J.,Sarnecki Michal^ORCID,Barouch Dan H.,Tipsuk Somporn,Stieh Daniel J.,Kroon Eugène,Schuetz Alexandra,Intasan Jintana,Sacdalan Carlo,Pinyakorn Suteeraporn,Grandin Pornsuk,Song Hongshuo,Tovanabutra Sodsai,Shubin Zhanna,Kim Dohoon^ORCID,Paquin-Proulx Dominic^ORCID,Eller Michael A.^ORCID,Thomas Rasmi^ORCID,de Souza Mark,Wieczorek Lindsay,Polonis Victoria R.,Pagliuzza Amélie,Chomont Nicolas^ORCID,Peter Lauren,Nkolola Joseph P.,Vingerhoets Johan,Truyers Carla,Pau Maria G.,Schuitemaker Hanneke,Phanuphak Nittaya,Michael Nelson,Robb Merlin L.^ORCID,Tomaka Frank L.,Ananworanich Jintanat

Funder

Henry M. Jackson Foundation

United States Department of Defense | Biometrics Identity Management Agency

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-020-0774-y.pdf

Reference31 articles.

1. Nakanjako, D. et al. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. AIDS 30, 1913–1922 (2016).

2. Deeks, G. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat. Med. 22, 839–850 (2016).